6/20
02:05 am
imcr
Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer [Yahoo! Finance]
Low
Report
Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer [Yahoo! Finance]
6/20
02:00 am
imcr
Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer
Low
Report
Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer
6/18
07:14 am
imcr
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma [Yahoo! Finance]
Medium
Report
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma [Yahoo! Finance]
6/18
07:00 am
imcr
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Medium
Report
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
6/5
12:10 pm
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
6/3
08:03 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.
High
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.
6/1
08:19 am
imcr
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response [Yahoo! Finance]
High
Report
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response [Yahoo! Finance]
6/1
08:00 am
imcr
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
High
Report
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
5/31
04:16 pm
imcr
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 [Yahoo! Finance]
High
Report
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 [Yahoo! Finance]
5/31
04:05 pm
imcr
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
High
Report
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
5/30
04:10 pm
imcr
Immunocore to present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Immunocore to present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
5/30
04:00 pm
imcr
Immunocore to present at the Jefferies Global Healthcare Conference
Medium
Report
Immunocore to present at the Jefferies Global Healthcare Conference
5/30
08:06 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
5/29
07:24 am
imcr
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma [Yahoo! Finance]
Low
Report
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma [Yahoo! Finance]
5/29
07:00 am
imcr
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
Low
Report
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
5/24
01:04 pm
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
5/24
08:04 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.
5/13
10:26 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Mizuho from $90.00 to $88.00. They now have a "buy" rating on the stock.
Medium
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Mizuho from $90.00 to $88.00. They now have a "buy" rating on the stock.
5/11
08:37 am
imcr
Analysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter Report [Yahoo! Finance]
Medium
Report
Analysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter Report [Yahoo! Finance]
5/9
03:39 pm
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its price target raised by analysts at Canaccord Genuity Group Inc. from $63.00 to $67.00. They now have a "hold" rating on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its price target raised by analysts at Canaccord Genuity Group Inc. from $63.00 to $67.00. They now have a "hold" rating on the stock.
5/9
02:05 pm
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its price target raised by analysts at HC Wainwright from $90.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its price target raised by analysts at HC Wainwright from $90.00 to $100.00. They now have a "buy" rating on the stock.
5/9
08:18 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.
5/8
07:08 am
imcr
Immunocore reports first quarter financial results and provides a business update [Yahoo! Finance]
Low
Report
Immunocore reports first quarter financial results and provides a business update [Yahoo! Finance]
5/8
07:00 am
imcr
Immunocore reports first quarter financial results and provides a business update
Low
Report
Immunocore reports first quarter financial results and provides a business update
5/2
07:27 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.